SGLT-2i Jardiance adds chronic heart failure indication
By Eo, Yun-Ho | translator Alice Kang
21.11.29 16:43:40
가나다라
0
Second in the SGLTi class to be approved after ‘Forxiga’… Provides benefits including reduced risk of hospitalization, etc.
Recently demonstrated efficacy in ‘acute’ conditions in EMPULSE study
According to industry sources, the Ministry of Food and Drug Safety had additionally approved a new indication for Jardiance (empagliflozin),' the SGLT-2 inhibitor used for the treatment of diabetes, to be used for adults with chronic heart failure with reduced left ventricular ejection fraction, regardless of their diabetes status.
With the approval, Jardiance became the second SGLT-2 inhibitor following ‘Forxiga (dapagliflozin)’ allowed to be prescribed for chronic heart failure. Forxiga had been approved for the same indication in December last year.
Jardiance's hear
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)